🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

325 results for “Disc” Clear

  1. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  2. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  3. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric peritoneal metastases

    phase 2 small molecule active

    1 trial

  4. Jardiance 10 mg film-coated tablets, BI 690517, Spironolacton Accord 25 mg filmomhulde tabletten, OMNIPAQUE 350 mg I/ml., AMINOHIPPURIC ACID

    Disc Medicine

    Heart failure, cardiovascular disease, chronic kidney disease

    phase 2 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Vulvar squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  7. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  8. LENALIDOMIDE, PYRIMETHAMINE, TOPIRAMATE

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  9. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

  10. LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1

    Disc Medicine

    B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma

    phase 2 small molecule active

    1 trial

  11. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  12. Leflunomide CF 20 mg, filmomhulde tabletten, Hydorxychloroquine 200mg/Placebo, Hydroxychloroquinesulfaat 200 mg Focus, filmomhulde tabletten, Hydroxychloroquinesulfaat CF 200 mg, filmomhulde tabletten, Leflunomide Mylan 10 mg, filmomhulde tabletten, Leflunomide 20mg/Placebo, Leflunomide Mylan 20 mg, filmomhulde tabletten, Plaquenil 200 mg, filmomhulde tabletten

    Disc Medicine

    primary Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  13. Lysergide D-tartrate, Placebo for Lysergide tartrate oral solution

    Disc Medicine

    Chronic cluster headache

    phase 2 small molecule active

    1 trial

  14. Matching placebo for Survodutide, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  15. Mekinist 0.5 mg film-coated tablets

    Disc Medicine

    Neurofibromatosis type 1

    phase 2 small molecule active

    1 trial

  16. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  17. Mesenchymal stem cells, Suspension and solvent for suspension for injection

    Disc Medicine

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  18. Mineral-enriched powder

    Disc Medicine

    Iron Deficiency

    phase 2 other completed

    1 trial

  19. NIVOLUMAB

    Disc Medicine

    Peritoneal Mesothelioma

    phase 2 small molecule active

    1 trial

  20. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  21. NaCl 0,9%, Deferoxamine Noridem 500mg Κόνις για ενέσιμο διάλυμα ή διάλυμα για έγχυση

    Disc Medicine

    Subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  22. Natriumthiosulfat 25%

    Disc Medicine

    Raynaud’s phenomenon

    phase 2 small molecule active

    1 trial

  23. OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

    Disc Medicine

    Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

    phase 2 small molecule active

    1 trial

  24. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources